import{j as s}from"./index-DFMeD_JO.js";function i(){return s.jsxs("div",{className:"max-w-3xl mx-auto p-4 space-y-4",children:[s.jsx("h1",{className:"text-2xl font-semibold",children:"References"}),s.jsxs("div",{className:"space-y-3 text-sm",children:[s.jsx("h2",{className:"font-medium",children:"Targets and rationale"}),s.jsxs("ul",{className:"list-disc ml-5",children:[s.jsx("li",{children:"AUC/MIC (mg·h/L) target 400–600 for serious MRSA to balance efficacy and nephrotoxicity."}),s.jsx("li",{children:"Trough alone is imperfect; AUC-guided dosing is recommended."})]}),s.jsx("h2",{className:"font-medium",children:"Monitoring strategy and timing"}),s.jsxs("ul",{className:"list-disc ml-5",children:[s.jsx("li",{children:"Obtain levels at steady state or after dose changes; use Bayesian when feasible."}),s.jsx("li",{children:"Recheck levels after 3–4 doses; monitor Scr daily in ICU."})]}),s.jsx("h2",{className:"font-medium",children:"Nephrotoxicity risk"}),s.jsx("ul",{className:"list-disc ml-5",children:s.jsx("li",{children:"Risk increases with AUC > 600; avoid AUC > 800 when possible."})}),s.jsx("h2",{className:"font-medium",children:"Special populations"}),s.jsx("ul",{className:"list-disc ml-5",children:s.jsx("li",{children:"Consider obesity, renal dysfunction, and critical illness when selecting dose."})}),s.jsx("h2",{className:"font-medium",children:"Citations"}),s.jsxs("ul",{className:"list-disc ml-5",children:[s.jsx("li",{children:"ASHP/IDSA Guidelines on Vancomycin Monitoring, 2020–2024."}),s.jsx("li",{children:"Institutional protocols and consensus statements."})]})]})]})}export{i as default};
